Cysteine

Cysteine

SCHEMBL26928643

NC(CS)C(=O)O.O=C1CCC(=O)N1

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A11 Q9UPY5 2/20 0.61
PTGS1 P23219 1/20 0.61
CRBN Q96SW2 2/20 0.42
GRM5 P41594 2/20 0.38
GRM1 Q13255 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
NFKB1 P19838 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
BLM P54132 1/20 0.38
KMT2A Q03164 1/20 0.38
FOLH1 Q04609 1/20 0.38
GRM3 Q14832 1/20 0.38
HIF1A Q16665 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
GRIK1 P39086 4/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cysteine SCHEMBL14956977 1.00 SLC7A11 (0.61) SLC7A11PTGS1CRBNGRM5GRM1
Cysteine SCHEMBL3447686 0.84 SLC7A11 (0.67) SLC7A11PTGS1GRM5GRM1KDM4E
Aspartic Acid SCHEMBL3460058 0.81 GRIK1 (0.44) SLC7A11CRBNGRM5GRM1KDM4E
Aspartic Acid SCHEMBL3460059 0.81 GRIK1 (0.44) SLC7A11CRBNGRM5GRM1KDM4E
Asparagine SCHEMBL27137678 0.79 GRIK1 (0.43) SLC7A11CRBNGRM5GRM1KDM4E
Cysteine SCHEMBL4289403 0.78
Cysteine SCHEMBL7898895 0.78 PTGS1 (1.00) SLC7A11PTGS1GRM5GRM1ALDH1A1
Cysteine SCHEMBL339562 0.78 PTGS1 (1.00) SLC7A11PTGS1GRM5GRM1ALDH1A1
Cysteine SCHEMBL21110883 0.78 PTGS1 (1.00) SLC7A11PTGS1GRM5GRM1ALDH1A1
Cysteine SCHEMBL95110 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399411-A1 SPECIFIC ANTIBODY-DRUG-CONJUGATES (ADCS) WITH KSP INHIBITORS AND ANTI-CD123-ANTIBODIES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2023-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399411-A1 SPECIFIC ANTIBODY-DRUG-CONJUGATES (ADCS) WITH KSP INHIBITORS AND ANTI-CD123-ANTIBODIES KIF23, SDCBP, KLK13 SLC7A11 1594/4885PTGS1 3559/4885CRBN 1721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.